Startups channel feed – Endpoints News

Startups channel feed

Serial biotech entrepreneur Michael Gilman takes his key to the $100M-plus club and goes all-in on drugging RNA

7 years ago

On a mission to make organ transplants safer and more durable, Blackstone gifts Talaris a new CEO, leads $100M round

7 years ago

Biotech startup grabs $27M launch round to pursue an R&D path blazed at Harvard and Boston Children’s

7 years ago

Achaogen’s bankruptcy and going-out-of-business sale offer a grim cautionary tale for the future of antibiotic development

7 years ago

Flagship unveils gut-focused upstart Kintai, with former GSK exec as chief

7 years ago

Alnylam spotlights just how good the efficacy data are for givosiran — tamping down on safety concerns

7 years ago

Sonde wants to listen for disease — M Ventures heard the Boston biotech, and led a $16M round to supercharge research

7 years ago

Romesh Subramanian births a new biotech with $50M and a plan to steer toward the clinic with drugs for rare muscle diseases

7 years ago

Belgian biotech founded by University of Torino team nabs $23.5 million in Series A round

7 years ago

Pfizer biotech spinout nabs $125M megaround as Bain-backed syndicate bets on its late-stage game plan

7 years ago

Dutch rare disease biotech ProQR carves out new company dedicated to epidermolysis bullosa

7 years ago

Biotech’s newborn unicorn Sana grabs Harvard tech aimed at slipping engineered stem cells past the immune system

7 years ago

Bone-marrow focused Imago BioSciences scores $40M in Omega-led round

7 years ago

Feng Zhang, heavyweight collaborators unveil latest CRISPR upstart — a diagnostic company

7 years ago

Arch-backed biotech hauls in a fast B round as its reborn anti-psychotic zooms to a PhII finish line

7 years ago

Surrozen banks $50M round to fuel its drive to the clinic with regenerative med platform

7 years ago

Deerfield takes translational partnership model to Harvard with $100M deal

7 years ago

Lundbeck fund backs a $50M launch round for SNIPR Biome, a new brand of CRISPR Cas biotech

7 years ago

Looking to capitalize on genetic modifiers, Maze Therapeutics launches with $191M in financing led by Arch, Third Rock

7 years ago

Blackstone antes $250M on its first big biotech bet, focused on a cardio drug spun out of Novartis

7 years ago

Serono spinoff Calypso Biotech becomes resident at J&J's European incubator, raises $22M+ in Series A

7 years ago

Backed by OrbiMed and J&J to build precision bacteria-killing tool, BiomX adds a slate of investors in $32M Series B

7 years ago

James Wilson turns to old mentor for gene therapy startup's star-studded $115M launch round

7 years ago

Ramaswamy's Axovant whips up a CNS spinoff with a $530M deal and a syndicate of supporters

7 years ago

First page Previous page 58 59 606162 63 64 Next page Last page